The U.S. Food and Drug Administration approved Novartis AG’s (NOVN.S) therapy for the treatment of patients with a type of advanced prostate cancer that has spread to other parts of the body, the drugmaker said.
Novartis’ Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments.
The company bought the therapy as part of its $2.1 billion purchase of cancer drugmaker Endocyte in 2018.
Pluvicto is a precision treatment combining a targeting compound, or ligand, with a cancer-killing radioactive particle, Novartis said.
The company said it has submitted marketing authorization for Pluvicto to the European Medicines Agency and other health authorities.
Two late-stage studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, according to Novartis.